Dictamnine ameliorates chronic itch in DNFB-induced atopic dermatitis mice via inhibiting MrgprA3

Anti‐inflammatory effect of dictamnine on allergic rhinitis via suppression of the LYN kinase‐mediated molecular signaling pathway during mast cell activation

“…Dictamnine has been reported to ameliorate dermatitis symptoms and inflammatory cytokine expression in dermatological diseases, such as atopic dermatitis (Dubinin et al, 1987). Dictamnine ameliorates chronic itch in dinitrofluorobenzene (DNFB)‐induced atopic dermatitis mice (Yang et al, 2023), inflammation in oxazolone‐induced mouse dermatitis (Lin et al, 2021), and inhibits anaphylactoid reactions via MRGPRX2 (Liu et al, 2021). In the present study, we investigated the anti‐AR effects of dictamnine by inhibiting MC activity and its underlying mechanisms.…”

“…In the present study, we investigated the anti‐AR effects of dictamnine by inhibiting MC activity and its underlying mechanisms. In both AR and dermatitis models, dictamnine suppresses pruritus in mice and inhibits MC infiltration and activation in lesions (Yang et al, 2023). Dictamnine inhibits the calcium flux of neuronal cells activated by both chloroquine and allyl isothiocyanate in the atopic dermatitis model, which is consistent with the inhibitory effect of dictamnine on intracellular calcium flux in MCs triggered by IgE or C48/80 (Liu et al, 2021).…”

“…Dictamnine inhibits the calcium flux of neuronal cells activated by both chloroquine and allyl isothiocyanate in the atopic dermatitis model, which is consistent with the inhibitory effect of dictamnine on intracellular calcium flux in MCs triggered by IgE or C48/80 (Liu et al, 2021). The mechanism by which dictamnine inhibits pruritus in atopic dermatitis is thought to involve the inhibition of the MrgprA3‐TRPA1 mediated histamine‐independent itch pathway (Yang et al, 2023). Moreover, targeting TRPA1 has been reported as a promising strategy for treating AR (Fang et al, 2021).…”

“…However, pharmacodynamic studies on dictamnine have not been abandoned. Dictamnine ameliorates chronic itch in DNFB‐induced atopic dermatitis mice by inhibiting MrgprA3 (Yang et al, 2023), and dictamnine ameliorates bone loss in ovariectomized osteoporosis by inhibiting the NF‐κB signal pathway and reducing reactive oxygen species (Wong et al, 2022). Although hepatotoxicity greatly influences the medicinal properties of small‐molecule compounds, it may be avoided by improving the delivery method, such as a PLGA‐nanocarrier‐encapsulated dictamnine (Lin et al, 2021).…”

“…Subsequent experiments were conducted 5 weeks after the first injection. The doses administered were determined by the previous report and preliminary experiments (Fu et al, 2018; Yang et al, 2023).…”